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Abstract The Rho/Rho-associated kinase (ROK) pathway has
been shown to modulate volume-regulated anion channels
(VRAC) in cultured calf pulmonary artery endothelial (CPAE)
cells. Since Rho/ROK can increase myosin light chain phosphor-
ylation, we have now studied the effects of inhibitors of myosin
light chain kinase (MLCK) or myosin light chain phosphatase
(MLCP) on VRAC in CPAE. Application of ML-9, an MLCK
inhibitor, inhibited VRAC, both when applied extracellularly or
when dialyzed into the cell. A similar inhibitory effect was
obtained by dialyzing the cells with AV25, a specific MLCK
inhibitory peptide. Conversely, NIPP1191ÿ210, an MLCP in-
hibitory peptide, potentiated the activation of VRAC by a 25%
hypotonic stimulus. These data indicate that activation of VRAC
is modulated by MLC phosphorylation.
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1. Introduction
Outwardly rectifying Cl3 channels regulated by changes in
cell volume (volume-regulated anion channels, VRAC) have
been described in many mammalian and non-mammalian cell
types (for reviews see [1^3]). These channels are involved in
several important physiological processes such as cell volume
regulation, transport of osmolytes, regulation of the mem-
brane potential and they may be required for progression
through the cell cycle [4]. In endothelial cells, VRAC can
also be activated by shear stress [5] suggesting an additional
role for VRAC in endothelial mechanosensitivity.
In spite of the well documented biophysical description of
ICl;swell (i.e. the Cl3 current through VRAC) in a wide panel of
cellular systems, it is still not understood which processes
control the gating of this channel. Several groups have pro-
vided evidence that VRAC activation requires one or more
protein (de)phosphorylation steps, but the identity of the ki-
nases (protein tyrosine kinases, PKC) or phosphatases as well
as their targets remain unknown and/or controversial [6^10].
We have proposed a pathway speci¢cally for vascular endo-
thelial cells whereby cell swelling reduces intracellular ionic
strength which triggers one or more tyrosine phosphorylation
steps that directly or indirectly activate VRAC [11,12]. In
addition, a role for GTP-binding proteins in the activation
of VRAC has been proposed since intracellular application
of GTPQS transiently activates VRAC in several cell types
[7,13^15]. Pretreatment with the Clostridium botulinum C3
exoenzyme which inactivates Rho GTPases by ADP-ribosyla-
tion, reduced the cell swelling-induced I3 e¥ux in intestinal
epithelial cells and ICl;swell in vascular endothelial cells [16,17].
Furthermore, Y-27632, a selective inhibitor of the Rho-asso-
ciated kinase ROK (also known as ROCK or Rho kinase;
one of the downstream targets for Rho) also inhibited
VRAC activity [17]. Thus, these data point to the Rho/
ROK pathway as a critical part in the signal transduction
cascade regulating VRAC.
Rho GTPase controls stress ¢ber formation via at least two
di¡erent downstream e¡ectors, Dia1 and ROK [18,19]. Dia1
induces pro¢lin-mediated actin polymerization [19], whereas
ROK promotes myosin light chain (MLC) phosphorylation
by phosphorylating the myosin binding subunit of MLC
phosphatase thereby inhibiting the phosphatase activity
[20,21]. In non-muscle cells, MLC phosphorylation is a pre-
requisite for actomyosin interaction and hence for stress ¢ber
assembly [22]. In addition, it is well accepted that cytoskeletal
components, including myosin, are key players in mechano-
sensing properties of endothelial cells [23,24].
Since on the one hand VRAC can be inhibited by inactivat-
ing Rho or ROK and on the other hand the Rho/ROK path-
way is a known activator of MLC phosphorylation, we inves-
tigated whether inhibitors of MLC phosphorylation and
dephosphorylation could a¡ect the activation of VRAC.
2. Materials and methods
2.1. Cell culture
Cultured calf pulmonary artery endothelial cells (CPAE, purchased
from American Type Culture Collection, ATCC, # CCL 209) were
grown in Dulbecco’s modi¢ed Eagle’s medium containing 10% human
serum, 2 mM L-glutamine, 2 U/ml penicillin and 2 mg/ml streptomy-
cin.
2.2. Solutions
The standard extracellular solution was a Krebs solution contain-
ing (in mM): 150 NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2, 10 glucose,
10 HEPES, pH 7.4 with NaOH. The osmolality of this solution, as
measured with a vapor pressure osmometer (Wescor 5500, Schlag,
Gladbach, Germany), was 320 þ 5 mOsm. At the beginning of the
patch-clamp recordings, the Krebs solution was replaced by an iso-
tonic Cs solution containing (in mM): 105 NaCl, 6 CsCl, 1 MgCl2,
1.5 CaCl2, 10 glucose, 90 mannitol, 10 HEPES, pH 7.4 with NaOH.
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 0 9 7 - 8
*Corresponding author. Fax: (32)-16-34 5991.
E-mail: bernd.nilius@med.kuleuven.ac.be
FEBS 23245 21-1-00
FEBS 23245FEBS Letters 466 (2000) 346^350
The 12.5% (280 þ 5 mOsm) and 25% (240 þ 5 mOsm) hypotonic solu-
tions (HTS) were obtained by omitting respectively 45 mM and 90
mM mannitol from this solution. In all experiments, a pipette solution
was used containing (in mM) 40 CsCl, 100 Cs-aspartate, 1 MgCl2,
1.93 CaCl2, 5 EGTA, 4 Na2ATP, 10 HEPES, pH 7.2 with CsOH (290
mOsm). The concentration of free Ca2 in this solution was bu¡ered
at 100 nM, which is below the threshold for activation of Ca2 acti-
vated Cl3 currents but su⁄cient for activation of VRAC by cell
swelling in CPAE cells. Only VRAC is activated under these condi-
tions. An accompanying background current through non-selective
cation channels is negligible (current density at +100 mV less than
5 pA/pF).
2.3. Inhibitors
The MLC kinase inhibitor, 1-(5-chloronaphthalene-1-sulfonyl)-1H-
hexahydro-1,4-diazepine hydrochloride (ML-9) [25] was purchased
from Sigma. More speci¢c inhibition of myosin light chain kinase
(MLCK) was obtained with the AV25 peptide [26] which was included
in the pipette solution at a concentration of 1 mM. The sequence of
AV25 is AKKLAKDRMKKYMARRKLQKAGHAV (2.93 kDa).
As a control peptide, which does not a¡ect MLCK activity, we
used a peptide derived from calponin (residues 145^163, p145ÿ163)
which is structurally similar to AV25. The control peptide (2.38
kDa, sequence AEKQQRRFQPEKLREGRNI) was also used at a
concentration of 1 mM in the pipette. Both peptides were synthesized
in the Peptide Synthesis Core Facility at the University of Calgary,
Alb., Canada. The inhibitory peptide for myosin light chain phos-
phatase (MLCP), NIPP1191ÿ210 (2.47 kDa, sequence RPKRKRKN-
SRVTFSEDDEII), and the mutated control peptide NIPP1191ÿ210
(V201A, F203A) (2.37 kDa, sequence RPKRKRKNSRATASED-
DEII) were synthesized at the KU Leuven [27].
2.4. Electrophysiological recordings
Currents were monitored with an EPC-9 (Heka Electronics, Lam-
brecht, Pfalz, Germany) patch-clamp ampli¢er. Patch electrodes had
DC resistances between 2 and 6 M6. An Ag-AgCl wire was used as
reference electrode. In Cl3 substitution experiments, a 3 M KCl-agar
bridge was used and membrane voltages were corrected for liquid
junction potentials if necessary. Whole-cell membrane currents were
measured using ruptured patches. Currents were sampled at 1 or 2 ms
intervals and ¢ltered at 500 or 200 Hz, respectively. Pipettes with a
resistance below 2 M6 were used to ensure e¡ective di¡usion of the
pipette solution into the cytosol. Between 50% and 70% of the series
resistance was electronically compensated to minimize voltage errors.
The following voltage protocol was applied every 15 s from a holding
potential of 320 mV: a step to 380 mV for 0.6 s, followed by a step
to 3100 mV for 0.2 s and a 2.6 s linear voltage ramp to +100 mV.
The time course of the whole-cell current at 3100 and +100 mV was
reconstructed from the currents recorded at these potentials during
successive voltage ramps. Current-voltage relations were obtained
from the currents measured during the linear voltage ramps. The
e¡ects of the tested inhibitors were determined when ICl; swell had
reached a stationary value.
2.5. Statistics
Experiments were performed at room temperature (22^25‡C).
Pooled data are given as the mean þ S.E.M. from n cells. Signi¢cance
was tested using Student’s paired or unpaired t-tests. Di¡erences were
considered signi¢cant at the level of P6 0.05.
3. Results
3.1. Inhibition of VRAC by MLCK blockers
To investigate the role of MLC phosphorylation in VRAC
activation we used ML-9 which is a well documented inhibitor
of smooth muscle MLCK [25] and which is also capable of
blocking agonist-induced MLC phosphorylation in endothe-
lial cells [28]. In a ¢rst approach, we activated ICl;swell with
25% HTS after which ML-9 (50 WM) was administered to the
bath solution. As shown in Fig. 1A,B, ML-9 exerted a rather
slow and voltage-independent inhibition of the pre-activated
ICl;swell. 50 WM ML-9 reduced the current density of ICl;swell
activated by 25% HTS at +100 mV to 61 þ 7% (n = 7, Fig. 1C).
The inhibitory e¡ect of ML-9 on ICl;swell was more pro-
Fig. 1. Block of VRAC by extracellularly applied ML-9. A: Time course of membrane current at +100 mV. ICl;swell was activated by 25% HTS
and 50 WM ML-9 was applied to the bath solution after ICl;swell had reached a constant level. Note the slow inhibition of the current by ML-9.
In the absence of ML-9 the current remains elevated during the HTS exposure (see also Fig. 2A). B: IV curves measured at the times indicated
in (A). Currents reversed at 317 mV which is close to the theoretical ECl of 325 mV. No shift in reversal potential was observed after applica-
tion of ML-9. Inhibition of ICl;swell is identical at all voltages. C: Pooled current amplitudes at +100 mV in the presence of 50 WM ML-9 and
normalized to the maximal current during HTS exposure, either 25% (n = 7) or 12.5% (n = 6). Note the stronger inhibition at the weaker hypo-
tonic stimulus.
FEBS 23245 21-1-00
B. Nilius et al./FEBS Letters 466 (2000) 346^350 347
nounced when a weaker hypotonic challenge (12.5% HTS)
was applied in which case the current amplitude was reduced
to 22 þ 11% of the control (n = 6, Fig. 1C).
In a second series of experiments we included ML-9 in the
patch pipette (50 WM). This signi¢cantly delayed the activa-
tion of VRAC during a 25% HTS stimulus (Fig. 2A). The
time to half-maximal activation of ICl;swell increased from
95 þ 16 s (n = 11) under control conditions (same batch of
cells) to 288 þ 42 s (n = 5) in the presence of 50 WM ML-9 in
the pipette. In addition, the maximal current density de-
creased at all potentials (not shown). At +100 mV, ML-9
induced a decrease of ICl;swell from 235 þ 43 (n = 4) to 32 þ 11
pA/pF (n = 5, Fig. 2C).
To further substantiate the role of MLCK in activating
VRAC and to verify that the ML-9 e¡ect was due to
MLCK inhibition (as opposed to a direct inhibition of
VRAC), we used a synthetic peptide (AV25) based on the
autoinhibitory domain of MLCK that has been shown to
block MLCK activity [26]. Activation of MLCK occurs via
a Ca2/calmodulin-induced conformational change that re-
moves the autoinhibitory domain from the active site, thereby
allowing access of its substrate myosin. The AV25 peptide
mimics the autoinhibitory domain by binding to the active
site and blocking access to myosin. As shown in Fig. 3, in-
clusion of AV25 (1 mM) in the pipette strongly reduced
VRAC activation by a 25% HTS stimulus. At +100 mV,
Fig. 2. Block of VRAC by ML-9 included in the patch pipette. A: Time course of membrane current at +100 mV in a control cell (open
circles) and a cell dialyzed with 50 WM ML-9 via the patch pipette (¢lled circles). Cells were challenged by 25% HTS as indicated by the solid
bars. B: Pooled data comparing the current densities of ICl;swell activated by 25% HTS at +100 mV in control cells and in cells dialyzed with
50 WM ML-9 via the pipette.
C
Fig. 3. Block of VRAC by the speci¢c MLCK inhibitory peptide
AV25. A: ICl;swell at +100 mV activated with 25% HTS in a control
cell (left) and in a cell dialyzed with 1 mM AV25 via the pipette
(right). Note the reduction in current amplitude and the slower acti-
vation. B: Current-voltage relationships measured at the times indi-
cated in (A) for the control cell (left) and the cell dialyzed with the
AV25 peptide (right). C: Pooled data from several cells comparing
the IV curves at +100 mV under control conditions, in the presence
of the AV25 peptide and in the presence of p145ÿ163, the calponin-
derived control peptide.
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ICl;swell reached 182 þ 13 pA/pF (n = 6) in control cells, but was
reduced to 21 þ 6 pA/pF (n = 5) in AV25-treated cells. A con-
trol peptide (p145ÿ163) which does not a¡ect MLCK activity,
did not signi¢cantly a¡ect ICl;swell (210 þ 22 pA/pF at +100
mV; n = 7) in comparison to non-treated cells. In addition
to the inhibition of the current amplitude, AV25 also delayed
ICl;swell activation similar to our observations with ML-9 (Fig.
2). The time to half-maximal activation at +100 mV was in-
creased to 261 þ 29 s (n = 5) in AV25-treated cells compared to
95 þ 16 s (n = 11) in control cells.
3.2. Potentiation of VRAC by a MLCP inhibitory peptide
If ML-9 and the AV25 peptide inhibit VRAC by blocking
MLCK activity, then it should also be possible to activate or
potentiate VRAC by blocking MLC dephosphorylation.
Smooth muscle MLCP is a type 1 serine/threonine protein
phosphatase (PP1) and the functional holoenzyme is com-
posed of three subunits: the N-isoform of the catalytic subunit
PP1C, the myosin-targeting subunit MYPT1 and a MYPT1-
associated protein of 20 kDa of unknown function [29]. Syn-
thetic peptides containing a RVXF-motif alleviate the inter-
action between the regulatory subunit and the catalytic sub-
unit PP1C and thereby destroy speci¢c properties of the
holoenzyme [30]. To functionally interfere with the MLCP
activity in CPAE cells, we used the synthetic peptide,
NIPP1191ÿ210, which includes the RVXF sequence (residues
200^203) of the nuclear regulator NIPP1 and which has
been shown to act as a competitor of various regulators of
PP1C [27].
When administered via the patch pipette, NIPP1191ÿ210
(1 mM) had no e¡ect on the basal current under isotonic
conditions. However, it signi¢cantly potentiated ICl;swell
evoked by 25% HTS (Fig. 4): 404 þ 47 pA/pF (n = 6) versus
221 þ 39 pA/pF (n = 7) in control cells (both at +100 mV). The
current potentiated by NIPP1191ÿ210 had a similar reversal
potential (between 325 and 315 mV) as ICl;swell in control
cells. In contrast, the control peptide NIPP1191ÿ210 (V201A,
F203A) which does not have a functional RVXF-motif, had
no e¡ect on ICl;swell when applied at 1 mM via the patch
pipette : 180 þ 30 pA/pF (n = 7) at +100 mV. The NIPP1191ÿ210
peptide did not signi¢cantly increase ICl;swell when cells were
stimulated with a weaker hypotonic stimulus (12.5% HTS):
154 þ 21 pA/pF (n = 5) at +100 mV in the presence of 1 mM
versus 127 þ 32 pA/pF (n = 7) at +100 mV in control cells.
4. Discussion
In this study we demonstrate that VRAC in macrovascular
endothelial cells is inhibited by blockers of MLCK and po-
tentiated by inhibition of MLCP, thereby identifying a func-
tional link between MLC phosphorylation and VRAC activa-
tion. An important question with respect to the underlying
mechanism is whether MLC phosphorylation directly partic-
ipates in the VRAC activation cascade or, alternatively,
whether MLC phosphorylation a¡ects VRAC activity indi-
rectly by setting the extent of cell swelling during a hypotonic
stimulus. We have recently shown that activation of ICl;swell
does not correlate with changes in cell volume and that a
decrease in intracellular ionic strength is the primary trigger
for channel activation [12]. This lack of correlation e¡ectively
excludes cell volume as the link between MLC phosphoryla-
tion and VRAC activity. We therefore conclude that MLC
phosphorylation is a critical parameter for one or more steps
in the VRAC activation cascade. This prompts the question
whether a mere increase in MLC phosphorylation is su⁄cient
to trigger VRAC activation. Several observations suggest a
negative answer to this question. First, thrombin which has
been shown to increase MLC phosphorylation via inhibition
of MLCP in endothelial cells [31] and also to activate endo-
thelial MLCK [32], does not activate VRAC under isotonic
conditions, although it can potentiate VRAC once it is
pre-activated by a hypotonic stimulus [33]. Second, the
Fig. 4. Potentiation of VRAC by an inhibitory peptide of MLCP. A: Time course of membrane current in CPAE cells at +100 and 3100 mV
in the presence of 1 mM NIPP1191ÿ210 peptide in the pipette during a 12.5 and 25% hypotonic stimulus. Note the extremely high current den-
sity at 25% HTS. B: Pooled data for CPAE cells, either control or treated with 1 mM of the active NIPP1191ÿ210 or the inactive NIPP1191ÿ210
(V201A, F203A) peptide (mean þ S.E.M. of current densities at +100 mV for 25% HTS).
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NIPP1191ÿ210 peptide, which acts as a competitor for the
RVXF-mediated interaction of various regulators with
PP1C, had no e¡ect on membrane current under isotonic con-
ditions. MLCK is activated in a Ca2/calmodulin-dependent
way [32]. Although there is no direct correlation between
[Ca2]i and VRAC [15], we have shown that a permissive
concentration of Ca2 is required to activate VRAC yet there
is no correlation between cytosolic Ca2 and VRAC activa-
tion [34]. It appears that MLC phosphorylation is required,
but not su⁄cient to activate VRAC in CPAE cells. A possible
explanation for such a permissive role could be that actomyo-
sin interaction which in non-muscle cells depends on MLC
phosphorylation [18], creates a sca¡old for proteins involved
in the VRAC activation cascade (for a discussion of the role
of the cytoskeleton in cell signaling, see [35]). Such a molec-
ular organization would then allow an e⁄cient transmission
of the primary trigger (reduction in ionic strength) to VRAC.
A positive correlation between on the one hand MLCK
activity and/or degree of MLC phosphorylation and on the
other hand transporter activity has also been reported for the
Na/K/2 Cl3 cotransporter in endothelial cells [36], and for
the Na/H antiporter in rat primary astrocytes [37]. How
MLCK activity or MLC phosphorylation determine Na/
K/2 Cl3 or cotransporter Na/H antiporter activity re-
mains to be established, but a MLC phosphorylation-depen-
dent organization of the activation cascade could be the com-
mon denominator.
Finally, our data are also compatible with a model whereby
the previously described e¡ects of the Rho/ROK pathway on
VRAC activity [17] are at least in part mediated via changes
in MLC phosphorylation.
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